• 식품과학과 산업
• /
• 제50권2호
• /
• pp.27-36
• /
• 2017

Today, the food packaging industry has a great interest in using active packaging to fresh food product as a solution for the future to positively provide its quality, safety and shelf life. Many researches have extensively studied functional packaging strategies in recently years. Controlled release packaging (CRP) is an innovative packaging technology in the packaging polymer matrix from which can active agents are delivered in a controlled way into the product. CRP technology is well-suited for controlling release of antimicrobial compounds and antioxidants to prevent food degradation reactions such as microbial growth and lipid oxidation. Advances in CRP technology allow food packaging manufacturers to challenge the development of better functional food packaging systems. This overview examines the most recent developments and technologies of active packaging for applying the food industry. The scope of this article has mainly been focused on controlled releasing systems.

• Journal of Pharmaceutical Investigation
• /
• 제31권1호
• /
• pp.19-25
• /
• 2001

The purpose of this study was to use a ternary polymeric matrix system for high drug loading of a highly soluble drug for controlled release delivery. The controlled drug delivery of diltiazem HCl (solubility > 50% in water at $25^{\circ}C$) with high loading dose (the final loading dose of drug was 34%) from a ternary polymeric matrix (gelatin, pectin, HPMC) was successfully accomplished. This simple monolithic system with 240 mg drug loading provided near zero-order release over a 24 hour-period by which time the system was completely dissolved. The release kinetics of diltiazem HCl tablet with high loading dose from the designed ternary polymeric system was dependent on the ratios of HPMC : pectin binary mixture. The release rate increased as pectin : HPMC ratio were increased. Swelling behavior of the ternary system and the ionic interaction of formulation components with cationic diltiazem molecule appear to control drug diffusion and the release kinetics. Comparable release profiles between commercial product and the designed system were obtained. The binding study between gelatin with diltiazem HCl showed the presence of two binding sites for drug interaction with subsequent controlled diffusion upon swelling. This designed delivery system is easy to manufacture and drug release behavior is highly reproducible and offers advantages over the existing commercial product.

• Journal of Pharmaceutical Investigation
• /
• 제41권4호
• /
• pp.217-225
• /
• 2011

The aim of this work was to prepare porous osmotic pump tablets for controlled delivery of Aceclofenac. Aceclofenac solid dispersion was prepared to improve the solubility by using the drug - carrier (Mannitol) ratio of 1:1. The osmotic pump tablets were prepared using the solid dispersed product of Aceclofenac. The formulation contains potassium chloride as osmotic agent, cellulose acetate as semipermeable membrane, poly ethylene glycol (PEG 4000) as pore former and sodium lauryl sulphate (SLS) as solubility enhancer. The formulations were designed by the general factors such as osmotic agent and pore former. All formulations were evaluated for various physical parameters and, the in vitro release studies were conducted as per USP. The drug release kinetic studies such as zero order, first order, and Higuchi and Korsmeyer peppas were determined and compared. All the formulations gave more controlled release compared to the marketed tablet studied. Numerical optimization techniques were applied to found out the best formulation by considering the parameter of in vitro drug release kinetics and dissolution profile standards. It was concluded that the porous osmotic pump tablets (F7) composed of Aceclofenac solid dispersion/Potassium chloride/Lactose/Sodium lauryl sulphate/Magnesium Stearate (400/40/95/10/5, mg/tab) and coating composition with Cellulose acetate/ PEG 4000 (60/40 %w/w) is the most satisfactory formulation. The porous osmotic pump tablets provide prolonged, controlled, and gastrointestinal environment-independent drug release.

• 한국시뮬레이션학회논문지
• /
• 제8권1호
• /
• pp.63-76
• /
• 1999

Recently in manufacturing environment, manufacturing order is characterized by unstable market demand, shorter product life cycle, a variety of product and shorter production lead time. In order to adapt this manufacturing order, flexible manufacturing systems(FMS) in manufacturing technology advances into the direction that machines become further versatile functionally and that tools are controlled by fast tool delivery device. Unlike conventional FMS to mainly focus on part flow, it is important to control tool flow in single-stage multimachine systems(SSMS), consisting of versatile machines and fast tool delivery device. This research is motivated by the thought that exact estimation of tool competition at part release in SSMS enhances the system performance. In this paper, in SSMS under dynamic tool allocation strategy to share tools among machines, we propose real-time part release and tool allocation algorithms which can apply real factory and which can improve system performance.

• 한국세라믹학회지
• /
• 제54권3호
• /
• pp.228-234
• /
• 2017

This work was achieved on the preparation of antimicrobial ceramic hybrid polyethylene films with natural chamomile extracts. The antimicrobial activity and various physicochemical properties of the prepared films were evaluated. Various natural products demonstrated antimicrobial activity. Among them, chamomile extracts showed strong activity and no cytotoxicity rather than that of the natural extracts. Porous ceramic materials were synthesized and demonstrated loading and controlled release of natural antimicrobial extracts. Furthermore, chamomile loaded ceramic hybrid films showed antimicrobial activity that was maintained for over 15 days.

• Journal of Pharmaceutical Investigation
• /
• 제40권1호
• /
• pp.63-66
• /
• 2010

The "Guidance Document for Bioequivalence Study" was revised for adding to bioequivalence studies of controlled-release products after meal(Korea Food & Drug Administration Notification #2008-22, 2008.5.7). The bioequivalence study design for controlled-release products is $2{\times}2$ crossover under fast and fed condition in respect. For studies of controlled-release products under fed study, the same high-fat diet should be taken within 20 minutes in at least a 10-hour fasting state. The drug products should be administered 30 minutes after the meal started. A high-fat(more than 35 percent of total caloric content of the meal) and high-calorie(over 900 calories) meal is recommended as a test meal for fed BE studies.

• 한국시뮬레이션학회:학술대회논문집
• /
• 한국시뮬레이션학회 1999년도 춘계학술대회 논문집
• /
• pp.60-64
• /
• 1999

Recently in manufacturing environment, manufacturing order is characterized by unstable market demand, shorter product life cycle, a variety of product and shorter production lead time. In order to adapt this manufacturing order, flexible manufacturing system(FMS) in manufacturing technology advances into the direction that machines become further versatile functionally and that tools are controlled by fast tool delivery device. Unlike conventional FMS to mainly focus on part flow, it is important to control tool flow in single-stage multimachine systems(SSMS), consisting of versatile machines and fast tool delivery device. In this paper, in SSMS under dynamic tool allocation strategy to share tools among machines, we propose real-time part release and tool allocation algorithms which can apply real factory and which can improve system performance.

• Journal of Pharmaceutical Investigation
• /
• 제30권3호
• /
• pp.179-189
• /
• 2000

Clebopride malate(Cm) is a new benzamide drug which has a potent central antidopaminergic activity possessing antiemetic and anxiolytic properties. A purpose of this study was to assess the feasibility of formulating sustained release preparation by dispersing a drug in hydrophilic polymeric matrices and double layered tablets(DLT), using HPMC, carbopol, PEO, PVP/VA and other polymers as a rate controlling barrier. The matrix and DLT showed optimum dissolution pattern up to 8 hours and the contents of polymer were optimized at 30% level in this preparation. After an oral administration in beagle dog, Cm concentration was determined by use of GC-ECD and pharmacokinetic parameters were calculated by Vallner's method. The AUC of DLT showed similar results and the duration of action was increased 55% compared to that of regular release dosage form. The calculated absorption rate effectiveness(ARE) and controlled release effectiveness(CRE) for DLT increased 50% compared to that of matrix, the overall effectiveness(E) of this product appears to be about 70%. in vivo effectiveness test, DLT showed significant differences from control on antiemetic action of Cm. In consequence, it was possible to conclude that double layered tablet might be a good candidate for the sustained release dosage forms.

• Journal of Pharmaceutical Investigation
• /
• 제40권spc호
• /
• pp.83-95
• /
• 2010

Over the years, nanoparticle drug delivery systems have demonstrated versatile potentials in biological, medical and pharmaceutical applications. In the pharmaceutical industry nanotechnology research has mainly focused on providing controlled drug release, targeting their delivery to specific organs, and developing parenteral formulations for poorly water soluble drugs to improve their bioavailability. Achievement in polymer industry has generated numerous polymers applicable to designing nanoparticles. From viewpoints of product development, a nanocarrier material should meet requirements for biodegradability, biocompatibility, availability, and regulatory approval crieteria. Albumin is indeed a material that fulfills such requirements. Also, the commercialization of a first albumin-bound paclitaxel nanoparticle product (Abraxane$^{TM}$) has sparked renewed interests in the application of albumin in the development of nanoparticle formulations. This paper reviews the intrinsic properties of albumin, its suitability as a nanocarrier material, and albumin-based parenteral formulation approaches. Particularly discussed in detail are albumin-based particulate injectables such as Abraxane$^{TM}$. Information on key roles of albumin in the nab$^{TM}$ technology and representative manufacturing processes of albumin particulate products are provided. It is likely that albumin-based particulate technology would extend its applications in delivering drugs, polypeptides, proteins, vaccines, nucleic acids, and genes.

• 폴리머
• /
• 제31권3호
• /
• pp.201-205
• /
• 2007

폴리락타이드, 폴리글리콜라이드, 및 글리콜라이드-락타이드 공중합체(PLGA)와 같은 생분해성 고분자들은 쉬운 약물방출량 조절과 부산물독성이 없이 지지체의 완벽한 분해과 좋은 생체적합성을 갖고 있다. 그러나 PLGA는 in vitro 실험에서의 괴상침식, 과도한 초기방출 후의 방출량이 감소하는 단점을 갖고 있다. 본 연구에서 PLGA 재결정 분말은 진공건조법을 이용하여 제조하였으며 1,3-bis(2-chloroethyl)-1-nitro-sourea(BCNU, carmustine)가 함유된 PLGA 웨이퍼의 방출거동을 알아보았으며 동시에 수용성 첨가제를 넣어 약물의 방출거동을 알아보고자 하였다. 진공건조법으로 재결정한 PLGA 웨이퍼가 일반방법으로 제조한 PLGA 웨이퍼보다 수분흡수율 감소와 웨이퍼 자체 초기의 분해 속도 감소로 인하여 초기 방출량이 감소하고 지속적 방출거동을 가지는 것을 확인하였다.